60 completed, 8 unknown, 1 active not recruiting, 1 not yet recruiting. 32 Phase 3, 15 Phase 4, 14 Phase 2, 2 Not applicable, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Completed 30, Unknown 2 |
| Phase 4 | 15 | Completed 12, Unknown 2, Active not recruiting 1 |
| Phase 2 | 14 | Completed 12, Unknown 2 |
| Not applicable | 2 | Completed 2 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow Encephalitis, Japanese: new trials by email Literature Review of Encephalitis, Japanese trials Research Report on Encephalitis, Japanese
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective Dengue, Chikungunya | Recruiting | Institut Pasteur du Cambodge | 10000 | 2025-12-18 | 2026-01-22 | |
| Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus Japanese Encephalitis | Not yet recruiting | ANRS, Emerging Infectious Diseases | 4000 | 2025-10-15 | 2025-09-11 | |
| A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 161 | 2025-02-24 | 2026-09-11 |
| Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas Liaoning Chengda Inactivated Japanese Encephalitis Vaccine - Japanese Encephalitis | Phase 4 | Active not recruiting | Liaoning Chengda Biotechnology CO., LTD | 250 | 2024-11-14 | 2024-12-13 |
| Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) Vero cell-drived inactive Japanese encephalitis vaccine, Measles-Mumps-Rubella Vaccine - Japanese Encephalitis, Measles | Phase 4 | Completed | Liaoning Chengda Biotechnology CO., LTD | 408 | 2024-03-02 | 2025-08-28 |
| Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization Japanese Encephalitis | Completed | Liaoning Chengda Biotechnology CO., LTD | 15357 | 2024-01-01 | 2025-08-28 | |
| An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Stamaril, Imojev, Ixiaro - Infectious Disease, Yellow Fever | Phase 2 | Unknown | Singapore General Hospital | 70 | 2022-09-28 | 2023-04-12 |
| Flavivirus Cross-priming Potential of IMOJEV IMOJEV - Japanese Encephalitis | Not applicable | Completed | University of Liverpool | 19 | 2021-04-16 | 2025-01-31 |
| Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province Japanese Encephalitis Vaccine (Vero Cell), Inactivated;, No prospective interventions - Japanese Encephalitis, Vaccine Preventable Disease | Phase 4 | Unknown | Zhejiang Provincial Center for Disease Control and Prevention | 712 | 2021-03-01 | 2022-11-15 |
| Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam JEVAX, JECEVAX - Japanese Encephalitis | Phase 3 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 655 | 2017-09-30 | 2018-09-17 |
| Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age JEVAX, JECEVAX - Japanese Encephalitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 220 | 2017-06-02 | 2018-09-17 |
| Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Live attenuated SA 14-14-2 Japanese Encephalitis vaccine, Measles, mumps, rubella vaccine - Encephalitis, Japanese, Measles | Phase 4 | Completed | PATH | 628 | 2016-10-13 | 2020-10-14 |
| Postmarketing Surveillance Study for IMOJEV® in Republic of Korea Japanese Encephalitis | Completed | Sanofi Pasteur, a Sanofi Company | 50 | 2016-07-21 | 2022-04-25 | |
| Purified Inactivated Japanese Encephalitis Vaccine Japanese Encephalitis Vaccine produced by IMBCAMS, Japanese Encephalitis Vaccine produced by Liaoning Chenda - Japanese Encephalitis Virus Disease | Phase 3 | Unknown | Chinese Academy of Medical Sciences | 1050 | 2015-09-01 | 2022-03-09 |
| Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Measles-Rubella combined vaccine(MR), Japanese Encephalitis alive vaccine(JE) - Measles, Rubella | Phase 4 | Completed | Centers for Disease Control and Prevention, China | 1043 | 2015-08-01 | 2016-08-01 |
| Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj Japanese encephalitis vaccine - Japanese Encephalitis | Phase 4 | Completed | Boryung Pharmaceutical Co., Ltd | 94 | 2015-08-01 | 2017-02-06 |
| Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine - Encephalitis, Japanese | Phase 4 | Completed | PATH | 561 | 2015-07-30 | 2020-10-19 |
| Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) - Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 250 | 2015-06-01 | 2022-03-28 |
| Safety and Immunogenicity of JECEVAX in Young Children JEVAX, JECEVAX-1, JECEVAX-0.8 - Japanese Encephalitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 200 | 2015-04-01 | 2016-06-28 |
| A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants 0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine, 0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine, 0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) - Encephalitis | Phase 3 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 900 | 2014-10-01 | 2016-09-01 |
Showing 20 of 72. Sign in to see all of them.
Encephalitis (6) · Measles (5) · Rubella (5) · Yellow Fever (5) · Mumps (4) · Chickenpox (3) · Hepatitis A (3) · Rabies (3) · Communicable Diseases (2) · Dengue (2) · Malaria (2) · Vaccine-Preventable Diseases (2) · Adenoviridae Infections (1) · Arenaviridae Infections (1)
Arbovirus Infections (72) · Brain Diseases (72) · Central Nervous System Diseases (72) · Central Nervous System Infections (72) · Central Nervous System Viral Diseases (72) · Encephalitis, Arbovirus (72) · Encephalitis, Viral (72) · Flaviviridae Infections (72) · Infections (72) · Infectious Encephalitis (72) · Mosquito-Borne Diseases (72) · Nervous System Diseases (72) · Neuroinflammatory Diseases (72) · RNA Virus Infections (72) · Flavivirus Infections (71)
Japanese Encephalitis Vaccines (10) · Blood Specimen Collection (3) · Hepatitis A Vaccines (3) · Measles-Mumps-Rubella Vaccine (2) · SA-14-14-2 vaccine (2) · Saline Solution (2) · Yellow Fever Vaccine (2) · Chickenpox Vaccine (1) · ChimeriVax (1) · Immunization, Secondary (1) · Immunoglobulins, Intravenous (1) · Measles Vaccine (1) · MenACWY-CRM vaccine (1) · Rabies Vaccines (1) · Ribavirin (1)
Valneva Austria GmbH (15) · Sanofi Pasteur, a Sanofi Company (11) · PATH (7) · Sanofi (7) · Liaoning Chengda Biotechnology CO., LTD (3) · National Institute of Hygiene and Epidemiology, Vietnam (3) · Boryung Pharmaceutical Co., Ltd (2) · Novartis (2) · Singapore General Hospital (2) · University of Liverpool (2) · ANRS, Emerging Infectious Diseases (1) · Centers for Disease Control and Prevention, China (1) · Changchun Keygen Biological Products Co., Ltd. (1) · Chinese Academy of Medical Sciences (1) · Chulalongkorn University (1)
China (8) · Thailand (8) · Australia (7) · Germany (7) · Philippines (7) · Austria (5) · South Korea (5) · United States (5) · Vietnam (5) · India (3) · Cambodia (2) · Laos (2) · Singapore (2) · Sri Lanka (2) · United Kingdom (2)
Astrid Kaltenboeck, Ph.D. (3) · Thiem D Vu, MD., PhD. (3) · Huanyu Wang (2) · Nihal Abeysinghe, MD, MSc (2) · Salvacion Gatchalian, MD (2) · Susanne Eder (2) · Susanne Eder, Mag. (2) · Vera Kadlecek, Mag. (2) · Ajit Rayamajhi, MBBS, MD (1) · Anand Dubey, M.D (1) · Andrea Ayad, Dr. (1) · Anu Kantele, MD PhD (1) · Atul Shanker, Dr. (1) · Bakul B. Javadekar, M.D. (1)
PMID 20934459, PMID 18394765, PMID 19143532, PMID 20856164, PMID 20864814, PMID 21150279, PMID 21288804, PMID 22696017, PMID 22777096, PMID 23967083, PMID 24656175, PMID 24717964, PMID 24873986, PMID 25239483, PMID 25308927, PMID 25483480, PMID 25567119, PMID 25872531, PMID 25886645, PMID 26005163, PMID 26994987, PMID 27628323, PMID 27686833, PMID 27815383, PMID 27903416, PMID 28135273, PMID 29081368, PMID 29325161, PMID 29429815, PMID 30833160, PMID 30962094, PMID 32156630, PMID 32474892, PMID 35243320, PMID 35714649, PMID 36969244, PMID 39794472, PMID 41980877